NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting<
27 Apr 2022

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF<
26 Apr 2022

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor
400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury<
25 Apr 2022

400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury

Decision from the first pre-specified futility analysis at 400 patients is expected in July
Cvrx reports first quarter 2022 financial and operating results<
25 Apr 2022

Cvrx reports first quarter 2022 financial and operating results

First quarter 2022 revenue of $4.1 million, a 43% increase over prior year
Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting<
11 Apr 2022

Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

We are encouraged by this data and look forward to further support the ongoing development of a uPARAPtargeting ADC in order to improve the outcome of our patients
Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke<
05 Apr 2022

Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke

ANA System Shown to Achieve High Rate of Complete Recanalization, Favorable 90 Day Outcomes
SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022<
31 Mar 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

Sparingvisionill be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis<
29 Mar 2022

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights<
23 Mar 2022

Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights

On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)<
21 Mar 2022

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)

AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка